AIMS/HYPOTHESIS: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. METHODS: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-(2)H3]cortisol (D cortisol) and [4-(13)C]cortisone ([(13)C]cortisone) were ingested, while [1,2,6,7-(3)H]cortisol ([(3)H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [(13)C]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. RESULTS: Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p < 0.05) over 6 h of the study. There was no difference (p = 0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [(13)C]cortisone to C13 cortisol was similar between groups. CONCLUSIONS/ INTERPRETATION: Hepatic conversion of [(13)C]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.
AIMS/HYPOTHESIS: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. METHODS: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabeticparticipants (LND), 21 overweight/obese non-diabeticparticipants (OND) and 20 overweight/obeseparticipants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-(2)H3]cortisol (D cortisol) and [4-(13)C]cortisone ([(13)C]cortisone) were ingested, while [1,2,6,7-(3)H]cortisol ([(3)H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [(13)C]cortisone to C13cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. RESULTS: Plasma D cortisol and C13cortisol concentrations were lower in OND than in LND (p < 0.05) over 6 h of the study. There was no difference (p = 0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [(13)C]cortisone to C13cortisol was similar between groups. CONCLUSIONS/ INTERPRETATION: Hepatic conversion of [(13)C]cortisone to C13cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.
Authors: J S Moore; J P Monson; G Kaltsas; P Putignano; P J Wood; M C Sheppard; G M Besser; N F Taylor; P M Stewart Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Eva Rask; Brian R Walker; Stefan Söderberg; Dawn E W Livingstone; Mats Eliasson; Owe Johnson; Ruth Andrew; Tommy Olsson Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: Rita Basu; Ravinder J Singh; Ananda Basu; Elizabeth G Chittilapilly; C Michael Johnson; Gianna Toffolo; Claudio Cobelli; Robert A Rizza Journal: Diabetes Date: 2004-08 Impact factor: 9.461
Authors: Katherine A Hughes; Konstantinos N Manolopoulos; Javaid Iqbal; Nicholas L Cruden; Roland H Stimson; Rebecca M Reynolds; David E Newby; Ruth Andrew; Fredrik Karpe; Brian R Walker Journal: Diabetes Date: 2012-04-17 Impact factor: 9.461
Authors: Santosh Renuse; Linda M Benson; Patrick M Vanderboom; F N U Ruchi; Yogesh R Yadav; Kenneth L Johnson; Benjamin C Brown; Jane A Peterson; Rita Basu; Daniel J McCormick; Akhilesh Pandey; Ananda Basu Journal: Clin Proteomics Date: 2022-05-19 Impact factor: 5.000
Authors: Anna J Anderson; Ruth Andrew; Natalie Z M Homer; Katherine A Hughes; Luke D Boyle; Mark Nixon; Fredrik Karpe; Roland H Stimson; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958
Authors: Anna J Anderson; Ruth Andrew; Natalie Z Homer; Gregory C Jones; Kenneth Smith; Dawn E Livingstone; Brian R Walker; Roland H Stimson Journal: J Clin Endocrinol Metab Date: 2016-07-26 Impact factor: 5.958